← All trials
NCT03538028
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 18, 2018
- Primary completion
- May 31, 2020
- Completion date
- May 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 55
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Carcinoma, Hepatocellular
- Melanoma
- Mesothelioma
- Ovarian Neoplasms
- Colorectal Neoplasms
- Carcinoma, Merkel Cell
- Lymphoma, Large B-Cell, Diffuse
- Endometrial Neoplasms
- Small Cell Lung Carcinoma
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.